What We're Reading: Page 242
Industry reads hand-picked by our editors
May 16, 2019
-
The Wall Street Journal
Opioid makers draw scrutiny from hedge funds
-
Nikkei Asian Review
Pharma group Lupin joins India's push into biosimilar drugs
-
The Salt Lake Tribune
Two crucial antibiotics are the first products of Utah's new nonprofit drug company
-
Barron's
Bluebird Bio’s Pricing Plan Worries One Biotech Analyst
May 15, 2019
May 14, 2019
-
The New York Times
Stem cell treatments flourish with little evidence that they work
-
South China Morning Post
Girl's death after rabies shot hits raw nerve in China after vaccine scandals
-
Healthcare Dive
Cancer patients face sticker shock under short-term plans, study finds
-
Vox
The cure for your next infection may come from sewage
May 13, 2019
-
The Wall Street Journal
How a Chinese Scientist Broke the Rules to Create the First Gene-Edited Babies
-
Reuters
Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions
-
BioCentury
White House, Congress considering killing Part D rebate rule, creating spending cap
-
MIT Technology Review
How biotech went from "no way" to payday in the cannabis business
May 10, 2019
-
BioCentury
White House, Pelosi discussing Part D deal
-
Associated Press
Trump backs Fla. plan to import lower-cost meds from abroad
-
The Wall Street Journal
Microbiome startup seeks to reassure investors on ethics
-
STAT
How Insys undermined an FDA effort to protect the public from dangerous opioids
May 09, 2019
-
Mother Jones
Big pharma has a big role on the federal committee tasked with curbing opioid abuse
-
CNN
Former Purdue Pharma president called addicted people 'victimizers' in emails
-
Bloomberg
Botox competitor aims to take market share as Allergan stumbles
-
The New York Times
Robert Pear, Authoritative Times Reporter on Health Care, Dies at 69
Previous
